The earnings beat is entirely illusory due to a restatement. The material weakness and loss of reliance on prior financials significantly increase litigation and delisting risk for this $5M market cap stock.
Price Chart
Executive Summary
HCW Biologics reported Q1 2026 EPS of $2.22, a 212.1% beat vs the -$1.98 consensus, but this is entirely due to a previously disclosed material misstatement in EPS calculation that overstated EPS by $0.80 per share. The company concurrently filed an 8-K (Item 4.02) stating it can no longer rely on its Q1 2026 financials and will restate them, severely undermining the credibility of this earnings release for a micro-cap company with a $5M market cap.
Key Financial Metrics
Key Facts
- Reported Q1 2026 EPS of $2.22 vs consensus of -$1.98 (212.1% beat)
- Concurrent 8-K (Item 4.02) filed stating Q1 2026 financials cannot be relied upon due to material misstatement in EPS calculation
- Company misapplied two-class method for EPS, overstating basic and diluted EPS by $0.80 per share
- Material weakness in internal controls over complex warrant accounting identified
- Company will restate Q1 2026 10-Q
Financial Impact
EPS overstated by $0.80 per share; restatement of Q1 2026 financials required; material weakness in internal controls identified
Risk Factors
- Delisting risk from Nasdaq due to late filing of restated 10-Q
- Increased litigation risk from shareholders following restatement announcement
- Potential loss of investor confidence and further capital market access issues for micro-cap company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345575 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | EFFECT | $1.26 | awaiting T+60 | — | $1.11 (+11.90%) |
Oct 2, 2026 23d ago | S-1 | $1.64 | awaiting T+60 | — | $1.11 (+32.32%) |
Oct 1, 2026 25d ago | DEF 14A | $1.69 | awaiting T+60 | — | $1.11 (+34.32%) |
Sep 24, 2026 4w ago | 8-K | $1.99 | awaiting T+60 | — | $1.11 (+44.22%) |
Aug 20, 2026 9w ago | S-1 | $2.12 | awaiting T+60 | — | $1.11 (−47.64%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.11 (+58.58%) |
Aug 14, 2026 10w ago | Press Release | $2.68 | awaiting T+60 | — | $1.11 (+58.58%) |
Aug 14, 2026 10w ago | 10-Q/A | $2.68 | awaiting T+60 | — | $1.11 (+58.58%) |
Aug 14, 2026 10w ago | 8-K | $2.68 | awaiting T+60 | — | $1.11 (+58.58%) |
Jul 29, 2026 12w ago | Press Release | $2.58 $1.12 | ▲ +56.59% | ▲ +61.32% | $1.11 (+56.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers